Biotech ETF Overview

With 16 ETFs traded in the U.S. markets, Biotech ETFs gather total assets under management of $14.68B. The average expense ratio is 0.76%. Biotech ETFs can be found in the following asset classes:

  • Equity

The largest Biotech ETF is the iShares NASDAQ Biotechnology ETF IBB with $6.98B in assets. In the last trailing year, the best performing Biotech ETF was the BBC at 46.74%. The most-recent ETF launched in the Biotech space was the Global X Genomics & Biotechnology ETF GNOM in 04/05/19.

Top ETF Performers

LABU Direxion Daily S&P Biotech Bull 3X Shares 2.34%
BBH VanEck Vectors Biotech ETF 2.17%
BBP Virtus LifeSci Biotech Products ETF 1.98%
FBT First Trust NYSE Arca Biotechnology Index Fund 1.57%
XBI SPDR S&P Biotech ETF 1.39%

Bottom ETF Performers

LABD Direxion Daily S&P Biotech Bear 3X Shares -6.33%
CNCR Loncar Cancer Immunotherapy ETF -4.67%
ZBIO ProShares UltraPro Short Nasdaq Biotechnology -3.38%
GNOM Global X Genomics & Biotechnology ETF -2.26%
BIS ProShares UltraShort Nasdaq Biotechnology -2.06%

Top Creations

IBB iShares NASDAQ Biotechnology ETF 56.65
FBT First Trust NYSE Arca Biotechnology Index Fund 7.74
CHNA Loncar China BioPharma ETF 0.61
BBH VanEck Vectors Biotech ETF 0
ZBIO ProShares UltraPro Short Nasdaq Biotechnology 0

Top Redemptions

XBI SPDR S&P Biotech ETF -105.16
LABD Direxion Daily S&P Biotech Bear 3X Shares -38.99
BIB ProShares Ultra NASDAQ Biotechnology -15.15
LABU Direxion Daily S&P Biotech Bull 3X Shares -6.95
PBE Invesco Dynamic Biotechnology & Genome ETF -5.54

AUM Winners

CHNA Loncar China BioPharma ETF 9.74%
XBI SPDR S&P Biotech ETF 5.41%
GNOM Global X Genomics & Biotechnology ETF 3.51%
BBP Virtus LifeSci Biotech Products ETF 1.30%
PBE Invesco Dynamic Biotechnology & Genome ETF 0.12%

AUM Losers

LABU Direxion Daily S&P Biotech Bull 3X Shares -7.61%
BBC Virtus LifeSci Biotech Clinical Trials ETF -7.57%
CNCR Loncar Cancer Immunotherapy ETF -5.95%
BIS ProShares UltraShort Nasdaq Biotechnology -5.74%
UBIO ProShares UltraPro Nasdaq Biotechnology -4.83%

Features and News

The Love & Hate Of Biotech ETFs

The volatile segment struggled to catch a break, then rallied, and now sits in the limelight of a virus outbreak.

ETF Report

Sectors In Review: January 2020

Sector ETFs had a great month, with most seeing positive returns.

ETF Report

 Sectors In Review: December 2019

A few sector ETFs faltered during the month

ETF Report

 Sectors In Review: November 2019

Sector ETFs did fairly well during the month, with a few exceptions

ETF Report

Sectors In Review: September 2019

Sector ETFs recorded largely positive performance during July.

ETF Report

Sectors In Review: June 2019

Health care and real estate struggled during the month.

Features and News

How To Know What’s In Your ETF

Our free tools and resources can help with your due diligence efforts.

ETF Report

Smart Beta: Beyond The Hype

Despite all the buzz, advisors have reasons to be wary of such strategies.

Features and News

Politics Weigh On Health Care ETFs

Fears of Medicare-for-all are weighing on health care ETFs. Is this an opportunity?